Skip to main content

Drug Interactions between tovorafenib and vadadustat

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

vadadustat tovorafenib

Applies to: vadadustat and tovorafenib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of CYP450 2C8 may increase the plasma concentrations and effects of tovorafenib, which has been found in vitro to be primarily metabolized by CYP450 2C8 and aldehyde oxidase, and to a lesser extent, by the isoenzymes CYP450 3A, 2C9, and 2C19. Increased plasma concentrations may increase the risk for adverse drug reactions including but not limited to, hemorrhage, skin toxicity, photosensitivity, hepatotoxicity, and reduced growth velocity in patients 18 years of age or younger. However, data from formal clinical drug interaction studies are not available.

MANAGEMENT: Caution is advised if tovorafenib is prescribed in combination with CYP450 2C8 inhibitors. Patients should be monitored for the development of hemorrhage, skin toxicity, photosensitivity, hepatotoxicity, and, in patients 18 years of age or younger, reduced growth velocity. Alternative therapy may need to be considered if a drug interaction is suspected.

Drug and food interactions

Moderate

vadadustat food

Applies to: vadadustat

Consumer information for this interaction is not currently available.

MONITOR: Smoking and alcohol consumption during therapy with vadadustat may increase the risk of gastrointestinal erosions. Serious erosions, including gastrointestinal bleeding and the need for red blood cell transfusions, have been reported during vadadustat clinical trials. Patients with a history of gastrointestinal erosion, peptic ulcer disease, and current tobacco smokers and alcohol drinkers may be at higher risk of gastrointestinal injury.

MANAGEMENT: Caution is advised if vadadustat is prescribed to current tobacco smokers or alcohol drinkers. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, hematemesis, trouble swallowing, chest or throat pain, and/or black, tarry stools.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer